8-K: NovoCure's METIS Trial Achieves Primary Endpoint, Showing Significant Delay in Brain Cancer Progression

NovoCure's phase 3 METIS trial demonstrated a statistically significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer treated with Tumor Treating Fields (TTFields) therapy.

Summary

• NovoCure's METIS trial, a phase 3 study, has met its primary endpoint, showing a statistically significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer (NSCLC).
• The trial involved 298 adult patients who had 1-10 brain metastases from NSCLC following stereotactic radiosurgery (SRS).
• Patients were randomized to receive either TTFields therapy with supportive care or supportive care alone.
• The median time to intracranial progression was 21.9 months for patients treated with TTFields therapy and supportive care, compared to 11.3 months for those receiving supportive care alone.
• This represents a hazard ratio of 0.67 with a p-value of 0.016, indicating a statistically significant result.
• The median duration of TTFields therapy was 16 weeks, with a median usage of 67%.
• While key secondary endpoints like time to neurocognitive failure, overall survival, and radiological response rate did not show statistical significance, some secondary endpoints, such as time to distant progression and quality of life, showed positive trends in favor of TTFields therapy.
• The company plans to submit these data to regulatory authorities and publish the findings in a peer-reviewed journal.

Sentiment

Score: 8

Explanation: The document presents very positive results from a clinical trial, with a statistically significant improvement in the primary endpoint. While some secondary endpoints did not reach significance, the overall tone is optimistic and suggests a potential breakthrough in treatment. The company's intention to seek regulatory approval further supports a positive outlook.

Positives

• The primary endpoint of the METIS trial was met, showing a significant delay in brain cancer progression with TTFields therapy.
• The median time to intracranial progression was almost doubled with TTFields therapy compared to supportive care alone (21.9 months vs 11.3 months).
• TTFields therapy was well-tolerated, maintaining quality of life and neurocognitive function.
• There were positive trends in secondary endpoints like time to distant progression and quality of life.
• The company intends to submit the data to regulatory authorities, potentially leading to expanded treatment options.

Negatives

• Key secondary endpoints, including time to neurocognitive failure, overall survival, and radiological response rate, did not demonstrate statistical significance.
• Full analysis of secondary endpoints is still ongoing, meaning the complete picture is not yet available.

Risks

• While the primary endpoint was met, the lack of statistical significance in key secondary endpoints could impact regulatory approval or market adoption.
• The full analysis of secondary endpoints is still pending, and the results could potentially reveal less favorable outcomes.
• The success of the therapy depends on patient compliance with the TTFields treatment, which requires consistent usage.

Future Outlook

Novocure intends to submit the METIS trial data to regulatory authorities and publish the findings in a peer-reviewed scientific journal. They also plan to share the results at an upcoming scientific congress.

Management Comments

• Asaf Danziger, Novocure's Chief Executive Officer, stated that the company is pleased with the positive outcome of the trial and encouraged by TTFields performance.
• Minesh Mehta, MD, Chief of Radiation Oncology at Miami Cancer Institute, noted that the use of TTFields therapy significantly delayed time to brain relapse, with associated improvement in quality of life and stable cognition, calling it a major benefit and potentially practice changing.

Industry Context

This announcement is significant in the oncology field, particularly for patients with brain metastases from NSCLC, where treatment options are limited and outcomes are often poor. The positive results from the METIS trial could position TTFields therapy as a valuable addition to the treatment landscape.

Comparison to Industry Standards

• The METIS trial results, showing a median time to intracranial progression of 21.9 months with TTFields therapy compared to 11.3 months with supportive care alone, are a significant improvement over typical outcomes for patients with brain metastases from NSCLC.
• Standard treatments like stereotactic radiosurgery (SRS) alone often result in rapid brain relapse, highlighting the potential of TTFields therapy to address this unmet need.
• While specific comparisons to other experimental therapies are not provided in this document, the hazard ratio of 0.67 and p-value of 0.016 suggest a clinically meaningful benefit compared to supportive care alone.
• The trial's design, including a blinded, independent radiologic review committee, adds credibility to the results.
• The fact that patients were allowed to crossover to the TTFields arm after second progression is a positive sign of the potential benefit of the therapy.

Stakeholder Impact

• Shareholders may react positively to the successful trial results, potentially increasing the company's stock value.
• Patients with brain metastases from NSCLC may benefit from a new treatment option.
• Healthcare providers may have a new tool to improve patient outcomes.
• The company's employees may be motivated by the positive results and the potential to help more patients.

Next Steps

• Novocure intends to submit the METIS trial data to regulatory authorities.
• The company plans to publish the findings in a peer-reviewed scientific journal.
• Novocure will share the results at an upcoming scientific congress.
• Full analysis of secondary endpoints is ongoing.

Key Dates

Keywords

Tumor Treating Fields, TTFields, brain metastases, non-small cell lung cancer, NSCLC, intracranial progression, stereotactic radiosurgery, METIS trial, oncology, cancer therapy